Shanghai Medicilon Inc (688202) — Capital Reinvestment Ratio
Latest as of June 2022:
3.63x
Shanghai Medicilon Inc (688202) has a Capital Reinvestment Ratio of 3.63x as of June 2022, meaning it reinvests 4% of its operating cash flow (CN¥9.55 Million) in capital expenditures (CN¥34.63 Million). See cash generation quality of Shanghai Medicilon Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
3.63x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥9.55 Million
CNY
Capital Expenditures
CN¥34.63 Million
CNY
Data as of
Jun 2022
Most recent filing
Shanghai Medicilon Inc Capital Reinvestment Ratio (2016–2025)
This chart tracks Shanghai Medicilon Inc's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Shanghai Medicilon Inc (2016–2025)
Year-by-year Capital Reinvestment Ratio for Shanghai Medicilon Inc from 2016 to 2025. For live market cap and broader valuation context, see 688202 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | CN¥105.17 Million | CN¥69.03 Million | ▼ -92.7% |
| 2023 | 9.01x | CN¥33.32 Million | CN¥300.10 Million | ▲ +1293.7% |
| 2021 | 0.65x | CN¥452.94 Million | CN¥292.71 Million | ▲ +13.1% |
| 2020 | 0.57x | CN¥207.77 Million | CN¥118.72 Million | ▼ -65.8% |
| 2019 | 1.67x | CN¥58.30 Million | CN¥97.38 Million | ▲ +84.5% |
| 2018 | 0.91x | CN¥71.11 Million | CN¥64.37 Million | ▲ +14.8% |
| 2017 | 0.79x | CN¥74.70 Million | CN¥58.91 Million | ▼ -31.5% |
| 2016 | 1.15x | CN¥34.13 Million | CN¥39.31 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow